Delveinsight
AUGUST 27, 2020
The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. Freenome secures USD 270 Million to boost its colorectal cancer blood test. White fat, in contrast, can build up and cause obesity.
XTalks
NOVEMBER 30, 2023
These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 24, 2021
It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. Non-COVID-19-Related.
XTalks
AUGUST 2, 2023
2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44
XTalks
DECEMBER 24, 2020
From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Antibody drugs were also developed as targeted COVID-19 treatments.
Expert insights. Personalized for you.
53 
Let's personalize your content